Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Prostate Cancer

Free Subscription Articles published in Anticancer Res Retrieve available abstracts of 125 articles: HTML format Text format

Single Articles

July 2018
1. TAMARI K, Oh RJ, Masai N, Shiomi H, et al
   Long-term Outcomes of Radiotherapy Regimen of 72 Gy in 30 Fractions for Prostate Cancer.
   Anticancer Res. 2018;38:4207-4212.
   PubMed     Text format     Abstract available
   
   
   
2. MIYAKE H, Matsushita Y, Watanabe H, Tamura K, et al
   Significance of De Ritis (Aspartate Transaminase/Alanine Transaminase) Ratio as a Significant Prognostic But Not Predictive Biomarker in Japanese Patients with Metastatic Castration-resistant Prostate Cancer Treated with Cabazitaxel.
   Anticancer Res. 2018;38:4179-4185.
   PubMed     Text format     Abstract available
   
   
   
3. MURAKAMI T, Obata H, Akitake N, Shiota M, et al
   Prognostic and Predictive Factors for Anti-androgen Withdrawal in Castration-resistant Prostate Cancer.
   Anticancer Res. 2018;38:4115-4121.
   PubMed     Text format     Abstract available
   
   
   
4. LIAO CH, Wu HC, Hu PS, Hsu SW, et al
   The Association of Matrix Metalloproteinase-1 Promoter Polymorphisms with Prostate Cancer in Taiwanese Patients.
   Anticancer Res. 2018;38:3907-3911.
   PubMed     Text format     Abstract available
   
   
   
5. LEIGHTON X, Bera A, Eidelman O, Eklund M, et al
   High ANXA7 Potentiates Eucalyptol Toxicity in Hormone-refractory Prostate Cancer.
   Anticancer Res. 2018;38:3831-3842.
   PubMed     Text format     Abstract available
   
   
   June 2018
6. JURECEKOVA J, Drobkova H, Sarlinova M, Babusikova E, et al
   The Role of Interleukin-6 Polymorphism (rs1800795) in Prostate Cancer Development and Progression.
   Anticancer Res. 2018;38:3663-3667.
   PubMed     Text format     Abstract available
   
   
   
7. ACUNA UM, Mo S, Zi J, Orjala J, et al
   Hapalindole H Induces Apoptosis as an Inhibitor of NF-kB and Affects the Intrinsic Mitochondrial Pathway in PC-3 Androgen-insensitive Prostate Cancer Cells.
   Anticancer Res. 2018;38:3299-3307.
   PubMed     Text format     Abstract available
   
   
   
8. VARGA L, Koszo RL, Fodor E, Cserhati A, et al
   Daily Setup Accuracy, Side-effects and Quality of Life During and After Prone Positioned Prostate Radiotherapy.
   Anticancer Res. 2018;38:3699-3705.
   PubMed     Text format     Abstract available
   
   
   
9. TRIGGIANI L, Colosini A, Buglione M, Pasinetti N, et al
   Exploring the Role of Enzalutamide in Combination with Radiation Therapy: An In Vitro Study.
   Anticancer Res. 2018;38:3487-3492.
   PubMed     Text format     Abstract available
   
   
   
10. POSFAI B, Kuthi L, Varga L, Laczo I, et al
    The Colorful Palette of Neuroendocrine Neoplasms in the Genitourinary Tract.
    Anticancer Res. 2018;38:3243-3254.
    PubMed     Text format     Abstract available
    
    
    May 2018
11. MARVASO G, Viola A, Fodor C, Jereczek-Fossa BA, et al
    Radiotherapy Plus Total Androgen Block Versus Radiotherapy Plus LHRH Analog Monotherapy for Non-metastatic Prostate Cancer.
    Anticancer Res. 2018;38:3139-3143.
    PubMed     Text format     Abstract available
    
    
    
12. PASQUALETTI F, Panichi M, Sainato A, Baldaccini D, et al
    Image-guided Stereotactic Body Radiotherapy in Metastatic Prostate Cancer.
    Anticancer Res. 2018;38:3119-3122.
    PubMed     Text format     Abstract available
    
    
    
13. OWARI T, Miyake M, Nakai Y, Morizawa Y, et al
    A Genitourinary Cancer-specific Scoring System for the Prediction of Survival in Patients with Bone Metastasis: A Retrospective Analysis of Prostate Cancer, Renal Cell Carcinoma, and Urothelial Carcinoma.
    Anticancer Res. 2018;38:3097-3103.
    PubMed     Text format     Abstract available
    
    
    
14. PORPIGLIA F, DE Luca S, Checcucci E, Garrou D, et al
    Comparing Image-guided targeted Biopsies to Radical Prostatectomy Specimens for Accurate Characterization of the Index Tumor in Prostate Cancer.
    Anticancer Res. 2018;38:3043-3047.
    PubMed     Text format     Abstract available
    
    
    
15. TRAMACERE F, Arcangeli S, Pignatelli A, Bracci S, et al
    Postoperative Hypofractionated Radiotherapy for Prostate Cancer.
    Anticancer Res. 2018;38:2951-2956.
    PubMed     Text format     Abstract available
    
    
    April 2018
16. UMEZAWA R, Inaba K, Nakamura S, Wakita A, et al
    Long-term Results of External Beam Radiotherapy for Prostate Cancer with Prostate-specific Antigen of More Than 50 ng/ml and Without Evidence of Lymph Node or Distant Metastasis.
    Anticancer Res. 2018;38:2303-2309.
    PubMed     Text format     Abstract available
    
    
    
17. TAKEZAWA Y, Izumi K, Machioka K, Iwamoto H, et al
    Crosstalk Between Androgen-sensitive and Androgen-insensitive Prostate Cancer Cells.
    Anticancer Res. 2018;38:2045-2055.
    PubMed     Text format     Abstract available
    
    
    
18. MASCAN B, Marignol L
    Aspirin in the Management of Patients with Prostate Cancer Undergoing Radiotherapy: Friend or Foe?
    Anticancer Res. 2018;38:1897-1902.
    PubMed     Text format     Abstract available
    
    
    
19. PEPE P, Pepe G, Pepe L, Garufi A, et al
    Cost-effectiveness of Multiparametric MRI in 800 Men Submitted to Repeat Prostate Biopsy: Results of a Public Health Model.
    Anticancer Res. 2018;38:2395-2398.
    PubMed     Text format     Abstract available
    
    
    March 2018
20. ZUGOR V, VON Brandenstein M, Akbarov I, Porres D, et al
    Preoperative Stating of Pelvic Lymph Nodes in Prostate Cancer Patients via Endorectal Magnetic Resonance Imaging.
    Anticancer Res. 2018;38:1763-1765.
    PubMed     Text format     Abstract available
    
    
    
21. VALERIANI M, Bonfili P, Reverberi C, Marinelli L, et al
    Moderate Hypofractionation in Patients with Low-risk Prostate Cancer: Long-term Outcomes.
    Anticancer Res. 2018;38:1671-1676.
    PubMed     Text format     Abstract available
    
    
    
22. GUO J, Yang J, Zhang X, Feng X, et al
    A Panel of Biomarkers for Diagnosis of Prostate Cancer Using Urine Samples.
    Anticancer Res. 2018;38:1471-1477.
    PubMed     Text format     Abstract available
    
    
    
23. KANEKO S, Sato C, Shiozawa N, Sato A, et al
    Suppressive Effect of Delta-Tocotrienol on Hypoxia Adaptation of Prostate Cancer Stem-like Cells.
    Anticancer Res. 2018;38:1391-1399.
    PubMed     Text format     Abstract available
    
    
    
24. LINNEY H, Barrett S
    Stereotactic Body Radiation Therapy for Patients with Early-stage Prostate Cancer.
    Anticancer Res. 2018;38:1231-1240.
    PubMed     Text format     Abstract available
    
    
    
25. SIEPE G, Buwenge M, Nguyen NP, Macchia G, et al
    Postoperative Hypofractionated Radiation Therapy in Prostate Carcinoma: A Systematic Review.
    Anticancer Res. 2018;38:1221-1230.
    PubMed     Text format     Abstract available
    
    
    
26. HOLMBERG AR, Marquez M, Lennartsson L, Meurling L, et al
    Synthesis and Binding of a Novel PSMA-specific Conjugate.
    Anticancer Res. 2018;38:1531-1537.
    PubMed     Text format     Abstract available
    
    
    February 2018
27. CHENG WL, Huang CY, Tai CJ, Chang YJ, et al
    Maspin Enhances the Anticancer Activity of Curcumin in Hormone-refractory Prostate Cancer Cells.
    Anticancer Res. 2018;38:863-870.
    PubMed     Text format     Abstract available
    
    
    
28. TANADINI-LANG S, Bogowicz M, Veit-Haibach P, Huellner M, et al
    Exploratory Radiomics in Computed Tomography Perfusion of Prostate Cancer.
    Anticancer Res. 2018;38:685-690.
    PubMed     Text format     Abstract available
    
    
    
29. NIEDER C, Kampe TA, Engljahringer K
    Does Patient-reported Dyspnea Reflect Thoracic Disease Characteristics in Patients with Incurable Cancer?
    Anticancer Res. 2018;38:901-904.
    PubMed     Text format     Abstract available
    
    
    January 2018
30. SERTDEMIR M, Weidner AM, Schoenberg SO, Morelli JN, et al
    Is There a Role for Functional MRI for the Assessment of Extracapsular Extension in Prostate Cancer?
    Anticancer Res. 2018;38:427-432.
    PubMed     Text format     Abstract available
    
    
    
31. SASAKI N, Yamazaki H, Shimizu D, Suzuki G, et al
    Long-term Outcomes of a Dose-reduction Trial to Decrease Late Gastrointestinal Toxicity in Patients with Prostate Cancer Receiving Soft Tissue-matched Image-guided Intensity-modulated Radiotherapy.
    Anticancer Res. 2018;38:385-391.
    PubMed     Text format     Abstract available
    
    
    
32. HERNROTH B, Holm I, Gondikas A, Tassidis H, et al
    Manganese Inhibits Viability of Prostate Cancer Cells.
    Anticancer Res. 2018;38:137-145.
    PubMed     Text format     Abstract available
    
    
    
33. MICHALSKA M, Schultze-Seemann S, Kuckuck I, Wolf P, et al
    In Vitro Evaluation of Humanized/De-immunized Anti-PSMA Immunotoxins for the Treatment of Prostate Cancer.
    Anticancer Res. 2018;38:61-69.
    PubMed     Text format     Abstract available
    
    
    
34. CHANG LW, Hung SC, Hu JC, Chiu KY, et al
    Retzius-sparing Robotic-assisted Radical Prostatectomy Associated with Less Bladder Neck Descent and Better Early Continence Outcome.
    Anticancer Res. 2018;38:345-351.
    PubMed     Text format     Abstract available
    
    
    December 2017
35. LAMB DS, Sondhauss S, Dunne JC, Woods L, et al
    Proteins Annexin A2 and PSA in Prostate Cancer Biopsies Do Not Predict Biochemical Failure.
    Anticancer Res. 2017;37:6943-6946.
    PubMed     Text format     Abstract available
    
    
    
36. HOFFMANN MA, Taymoorian K, Ruf C, Gerhards A, et al
    Diagnostic Performance of Multiparametric Magnetic Resonance Imaging and Fusion Targeted Biopsy to Detect Significant Prostate Cancer.
    Anticancer Res. 2017;37:6871-6877.
    PubMed     Text format     Abstract available
    
    
    
37. MAYER MJ, Klotz LH, Venkateswaran V
    Evaluating Metformin as a Potential Chemosensitizing Agent when Combined with Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Cells.
    Anticancer Res. 2017;37:6601-6607.
    PubMed     Text format     Abstract available
    
    
    
38. HAGELGANS A, Jandeck C, Friedemann M, Donchin A, et al
    Identification of CpG Sites of SERPINA5 Promoter with Opposite Methylation Patterns in Benign and Malignant Prostate Cells.
    Anticancer Res. 2017;37:6609-6618.
    PubMed     Text format     Abstract available
    
    
    November 2017
39. YANG Y, Li X, Mamouni K, Kucuk O, et al
    Mifepristone Has Limited Activity to Enhance the In Vivo Efficacy of Docetaxel and Enzalutamide Against Bone Metastatic and Castration-Resistant Prostate Cancer.
    Anticancer Res. 2017;37:6235-6243.
    PubMed     Text format     Abstract available
    
    
    
40. MUSA MA, Latinwo LM, Joseph MY, Badisa VL, et al
    Identification of 7,8-Diacetoxy-3-Arylcoumarin Derivative as a Selective Cytotoxic and Apoptosis-inducing Agent in a Human Prostate Cancer Cell Line.
    Anticancer Res. 2017;37:6005-6014.
    PubMed     Text format     Abstract available
    
    
    October 2017
41. SHIMIZU D, Yamazaki H, Nishimura T, Aibe N, et al
    Long-term Tumor Control and Late Toxicity in Patients with Prostate Cancer Receiving Hypofractionated (2.2 Gy) Soft-tissue-matched Image-guided Intensity-modulated Radiotherapy.
    Anticancer Res. 2017;37:5829-5835.
    PubMed     Text format     Abstract available
    
    
    
42. MACCHIA G, Siepe G, Capocaccia I, Nguyen NP, et al
    Hypofractionated Postoperative IMRT in Prostate Carcinoma: A Phase I/II Study.
    Anticancer Res. 2017;37:5821-5828.
    PubMed     Text format     Abstract available
    
    
    
43. IWAMA K, Yamazaki H, Shimizu D, Suzuki G, et al
    Interfractional Rectal Displacement Requiring Repeated Precaution Did Not Correlate to Biochemical Control and Rectal Toxicity in Patients with Prostate Cancer Treated with Image-guided Intensity-modulated Radiation Therapy.
    Anticancer Res. 2017;37:5755-5760.
    PubMed     Text format     Abstract available
    
    
    
44. OBATA H, Shiota M, Akitake N, Takeuchi A, et al
    Differential Risk of Castration Resistance After Initial Radical Prostatectomy or Radiotherapy for Prostate Cancer.
    Anticancer Res. 2017;37:5631-5637.
    PubMed     Text format     Abstract available
    
    
    
45. IZUMI K, Shigehara K, Nohara T, Narimoto K, et al
    Both High and Low Serum Total Testosterone Levels Indicate Poor Prognosis in Patients with Prostate Cancer.
    Anticancer Res. 2017;37:5559-5564.
    PubMed     Text format     Abstract available
    
    
    
46. HUTCHINSON J, Marignol L
    Clinical Potential of Statins in Prostate Cancer Radiation Therapy.
    Anticancer Res. 2017;37:5363-5372.
    PubMed     Text format     Abstract available
    
    
    September 2017
47. VON HARDENBERG J, Schwartz M, Werner T, Fuxius S, et al
    Prospective Evaluation of Neuromediator Dynamics in Castration-Resistant Prostate Cancer Patients During Docetaxel.
    Anticancer Res. 2017;37:5117-5124.
    PubMed     Text format     Abstract available
    
    
    
48. WU X, Reinikainen P, Kapanen M, Vierikko T, et al
    Diffusion-weighted MRI Provides a Useful Biomarker for Evaluation of Radiotherapy Efficacy in Patients with Prostate Cancer.
    Anticancer Res. 2017;37:5027-5032.
    PubMed     Text format     Abstract available
    
    
    
49. ORYWAL K, Jelski W, Werel T, Szmitkowski M, et al
    The Diagnostic Significance of Serum Alcohol Dehydrogenase Isoenzymes and Aldehyde Dehydrogenase Activity in Prostate Cancer Patients.
    Anticancer Res. 2017;37:4961-4965.
    PubMed     Text format     Abstract available
    
    
    
50. WIKSTROM J, Isacsson U, Johansson B, Lennernas BO, et al
    Magnetic Resonance Compatibility of a Transponder Aimed for Radiotherapy Positioning - A Phantom Study.
    Anticancer Res. 2017;37:4993-4996.
    PubMed     Text format     Abstract available
    
    
    August 2017
51. YU S, Jiang Y, Wan F, Wu J, et al
    Immortalized Cancer-associated Fibroblasts Promote Prostate Cancer Carcinogenesis, Proliferation and Invasion.
    Anticancer Res. 2017;37:4311-4318.
    PubMed     Text format     Abstract available
    
    
    
52. LIN C, Wang J, Wang Y, Zhu P, et al
    GRP78 Participates in PCA3-regulated Prostate Cancer Progression.
    Anticancer Res. 2017;37:4303-4310.
    PubMed     Text format     Abstract available
    
    
    
53. SOBKOWICZ AD, Sanders AJ, Mason MD, Jiang WG, et al
    Potential Implication of Paxillin in Cancer Establishment Within the Bone Environment.
    Anticancer Res. 2017;37:4255-4268.
    PubMed     Text format     Abstract available
    
    
    
54. HUNG SC, Yang CK, Cheng CL, Ou YC, et al
    Long-term Oncologic Outcomes of Robotic-assisted Radical Prostatectomy by a Single Surgeon.
    Anticancer Res. 2017;37:4157-4164.
    PubMed     Text format     Abstract available
    
    
    July 2017
55. DETTI B, D'Angelillo RM, Ingrosso G, Olmetto E, et al
    Combining Abiraterone and Radiotherapy in Prostate Cancer Patients Who Progressed During Abiraterone Therapy.
    Anticancer Res. 2017;37:3717-3722.
    PubMed     Text format     Abstract available
    
    
    
56. MIYAZAWA Y, Takahiro S, Yoshitaka S, Nomura M, et al
    Evaluation of Bone Turnover / Quality Markers and Bone Mineral Density in Prostate Cancer Patients Receiving Androgen Deprivation Therapy with or without Denosumab.
    Anticancer Res. 2017;37:3667-3671.
    PubMed     Text format     Abstract available
    
    
    
57. OZGUR E, Celik AI, Darendeliler E, Gezer U, et al
    PCA3 Silencing Sensitizes Prostate Cancer Cells to Enzalutamide-mediated Androgen Receptor Blockade.
    Anticancer Res. 2017;37:3631-3637.
    PubMed     Text format     Abstract available
    
    
    
58. WINTERS B, Brown L, Coleman I, Nguyen H, et al
    Inhibition of ERG Activity in Patient-derived Prostate Cancer Xenografts by YK-4-279.
    Anticancer Res. 2017;37:3385-3396.
    PubMed     Text format     Abstract available
    
    
    June 2017
59. HU JC, Hung SC, Ou YC
    Assessments of Neoadjuvant Hormone Therapy Followed by Robotic-Assisted Radical Prostatectomy for Intermediate- and High-Risk Prostate Cancer.
    Anticancer Res. 2017;37:3143-3150.
    PubMed     Text format     Abstract available
    
    
    
60. HONDA M, Yogosawa S, Kamada M, Kamata Y, et al
    A Novel Near-infrared Fluorescent Protein, iRFP720, Facilitates Transcriptional Profiling of Prostate Cancer Bone Metastasis in Mice.
    Anticancer Res. 2017;37:3009-3013.
    PubMed     Text format     Abstract available
    
    
    
61. FITZPATRICK C, Lynch O, Marignol L
    68Ga-PSMA-PET/CT Has a Role in Detecting Prostate Cancer Lesions in Patients with Recurrent Disease.
    Anticancer Res. 2017;37:2753-2760.
    PubMed     Text format     Abstract available
    
    
    
62. PEPE P, Garufi A, Priolo GD, Pennisi M, et al
    Multiparametric MRI/TRUS Fusion Prostate Biopsy: Advantages of a Transperineal Approach.
    Anticancer Res. 2017;37:3291-3294.
    PubMed     Text format     Abstract available
    
    
    
63. KRUCK S, Hennenlotter J, Amend B, Geiger M, et al
    Chronic Periodontitis Does Not Impact Serum Levels of Prostate-specific Antigen.
    Anticancer Res. 2017;37:3163-3167.
    PubMed     Text format     Abstract available
    
    
    April 2017
64. JOHANSSON AK, Lennernas B, Isacsson U
    Neurovascular Bundle Infiltration Can Explain Local Relapses Using Conformal Radiotherapy of Prostate Cancer.
    Anticancer Res. 2017;37:1825-1830.
    PubMed     Text format     Abstract available
    
    
    
65. PARK J, Joung JY, Hwang JE, Hong D, et al
    Ninjurin1 Is Up-regulated in Circulating Prostate Tumor Cells and Plays a Critical Role in Prostate Cancer Cell Motility.
    Anticancer Res. 2017;37:1687-1696.
    PubMed     Text format     Abstract available
    
    
    
66. MABUCHI M, Ueda M, Yoshida Y, Horiike K, et al
    Systematic Trial for Evaluating Docetaxel in a Human Prostate Cancer Cell DU145 Xenograft Model.
    Anticancer Res. 2017;37:1665-1676.
    PubMed     Text format     Abstract available
    
    
    
67. OU YC, Hung SC, Hwang LH, Yang CK, et al
    Salvage Robotic-assisted Laparoscopic Radical Prostatectomy: Experience with 14 Cases.
    Anticancer Res. 2017;37:2045-2050.
    PubMed     Text format     Abstract available
    
    
    March 2017
68. CICERO G, DE Luca R, Dorangricchia P, Dieli F, et al
    The Clinical Efficacy of Enzalutamide in Metastatic Prostate Cancer: Prospective Single-center Study.
    Anticancer Res. 2017;37:1475-1480.
    PubMed     Text format     Abstract available
    
    
    
69. PALUMBO I, Matrone F, Montesi G, Bellavita R, et al
    Statins Protect Against Acute RT-related Rectal Toxicity in Patients with Prostate Cancer: An Observational Prospective Study.
    Anticancer Res. 2017;37:1453-1457.
    PubMed     Text format     Abstract available
    
    
    
70. HENKENBERENS C, VON Klot CA, Ross TL, Bengel FM, et al
    68Ga-PSMA Ligand PET/CT-based Radiotherapy for Lymph Node Relapse of Prostate Cancer After Primary Therapy Delays Initiation of Systemic Therapy.
    Anticancer Res. 2017;37:1273-1279.
    PubMed     Text format     Abstract available
    
    
    
71. SCIALPI M, Prosperi E, D'Andrea A, Martorana E, et al
    Biparametric versus Multiparametric MRI with Non-endorectal Coil at 3T in the Detection and Localization of Prostate Cancer.
    Anticancer Res. 2017;37:1263-1271.
    PubMed     Text format     Abstract available
    
    
    
72. ELLIS-CALEO T, Hegde JV, Bath S, Mesko S, et al
    Imaging and Pathology Correlations for Different Risk Stratification Models for Intermediate-risk Prostate Cancer.
    Anticancer Res. 2017;37:1237-1242.
    PubMed     Text format     Abstract available
    
    
    
73. WINDRICHOVA J, Fuchsova R, Kucera R, Topolcan O, et al
    MIC1/GDF15 as a Bone Metastatic Disease Biomarker.
    Anticancer Res. 2017;37:1501-1505.
    PubMed     Text format     Abstract available
    
    
    February 2017
74. MESSINA CS, Weiher H, Schmidt-Wolf IG
    Targeting Prostate Cancer with a Combination of WNT Inhibitors and a Bi-functional Peptide.
    Anticancer Res. 2017;37:555-559.
    PubMed     Text format     Abstract available
    
    
    
75. LERTSUWAN K, Peters W, Johnson L, Lertsuwan J, et al
    Purinergic Receptor Expression and Cellular Responses to Purinergic Agonists in Human Prostate Cancer Cells.
    Anticancer Res. 2017;37:529-537.
    PubMed     Text format     Abstract available
    
    
    
76. ABLIN RJ, Owen S, Jiang WG
    Prostate Transglutaminase (TGase-4) Induces Epithelial-to-Mesenchymal Transition in Prostate Cancer Cells.
    Anticancer Res. 2017;37:481-487.
    PubMed     Text format     Abstract available
    
    
    
77. FANDELLA A, Scattoni V, Galosi A, Pepe P, et al
    Italian Prostate Biopsies Group: 2016 Updated Guidelines Insights.
    Anticancer Res. 2017;37:413-424.
    PubMed     Text format     Abstract available
    
    
    January 2017
78. DONDOO TO, Fukumori T, Daizumoto K, Fukawa T, et al
    Galectin-3 Is Implicated in Tumor Progression and Resistance to Anti-androgen Drug Through Regulation of Androgen Receptor Signaling in Prostate Cancer.
    Anticancer Res. 2017;37:125-134.
    PubMed     Text format     Abstract available
    
    
    December 2016
79. YAMAGUCHI H, Hori M, Suzuki O, Seo Y, et al
    Clinical Significance of the Apparent Diffusion Coefficient Ratio in Prostate Cancer Treatment with Intensity-modulated Radiotherapy.
    Anticancer Res. 2016;36:6551-6556.
    PubMed     Text format     Abstract available
    
    
    
80. THELLENBERG-KARLSSON C, Nyman C, Nilsson S, Blom R, et al
    Bone-targeted Novel Cytotoxic Polybisphosphonate Conjugate in Castration-resistant Prostate Cancer: A Multicenter Phase 1 Study.
    Anticancer Res. 2016;36:6499-6504.
    PubMed     Text format     Abstract available
    
    
    
81. STRANDBERG S, Karlsson CT, Ogren M, Axelsson J, et al
    11C-Acetate-PET/CT Compared to 99mTc-HDP Bone Scintigraphy in Primary Staging of High-risk Prostate Cancer.
    Anticancer Res. 2016;36:6475-6479.
    PubMed     Text format     Abstract available
    
    
    
82. JOENSUU T, Joensuu G, Kairemo K, Kiljunen T, et al
    Multimodal Primary Treatment of Metastatic Prostate Cancer with Androgen Deprivation and Radiation.
    Anticancer Res. 2016;36:6439-6447.
    PubMed     Text format     Abstract available
    
    
    
83. TSAI PH, Cheng CH, Lin CY, Huang YT, et al
    Dietary Flavonoids Luteolin and Quercetin Suppressed Cancer Stem Cell Properties and Metastatic Potential of Isolated Prostate Cancer Cells.
    Anticancer Res. 2016;36:6367-6380.
    PubMed     Text format     Abstract available
    
    
    November 2016
84. KATO H, Furuya Y, Miyazawa Y, Miyao T, et al
    Consequences of an Early PSA Response to Enzalutamide Treatment for Japanese Patients with Metastatic Castration-resistant Prostate Cancer.
    Anticancer Res. 2016;36:6141-6149.
    PubMed     Text format     Abstract available
    
    
    
85. KIM SH, Kim KY, Yu SN, Park SG, et al
    Monensin Induces PC-3 Prostate Cancer Cell Apoptosis via ROS Production and Ca2+ Homeostasis Disruption.
    Anticancer Res. 2016;36:5835-5843.
    PubMed     Text format     Abstract available
    
    
    
86. LAO L, Shen J, Tian H, Yao Q, et al
    Secreted Phosphoprotein 24 kD Inhibits Growth of Human Prostate Cancer Cells Stimulated by BMP-2.
    Anticancer Res. 2016;36:5773-5780.
    PubMed     Text format     Abstract available
    
    
    
87. BURONI FE, Persico MG, Pasi F, Lodola L, et al
    Radium-223: Insight and Perspectives in Bone-metastatic Castration-resistant Prostate Cancer.
    Anticancer Res. 2016;36:5719-5730.
    PubMed     Text format     Abstract available
    
    
    October 2016
88. CHELLURI R, Caza T, Woodford MR, Reeder JE, et al
    Valproic Acid Alters Angiogenic and Trophic Gene Expression in Human Prostate Cancer Models.
    Anticancer Res. 2016;36:5079-5086.
    PubMed     Text format     Abstract available
    
    
    September 2016
89. OU YC, Weng WC, Chang KS, Mei CE, et al
    Prophylactic Robotic-assisted Laparoscopic Radical Prostatectomy for Preoperative Suspicion of Prostate Cancer: Experience with 55 Cases.
    Anticancer Res. 2016;36:4895-901.
    PubMed     Text format     Abstract available
    
    
    
90. KULDA V, Topolcan O, Kucera R, Kripnerova M, et al
    Prognostic Significance of TMPRSS2-ERG Fusion Gene in Prostate Cancer.
    Anticancer Res. 2016;36:4787-93.
    PubMed     Text format     Abstract available
    
    
    
91. SMITH AD, Truong M, Bristow R, Yip P, et al
    The Utility of Serum CA9 for Prognostication in Prostate Cancer.
    Anticancer Res. 2016;36:4489-92.
    PubMed     Text format     Abstract available
    
    
    
92. PORPIGLIA F, DE Luca S, Passera R, Manfredi M, et al
    Multiparametric-Magnetic Resonance/Ultrasound Fusion Targeted Prostate Biopsy Improves Agreement Between Biopsy and Radical Prostatectomy Gleason Score.
    Anticancer Res. 2016;36:4833-9.
    PubMed     Text format     Abstract available
    
    
    
93. SHIDA Y, Hakariya T, Takehara K, Onita T, et al
    Comparison Between a Combined Transrectal and Transperineal Approach and a Transrectal Approach for Prostate Rebiopsy.
    Anticancer Res. 2016;36:4685-90.
    PubMed     Text format     Abstract available
    
    
    August 2016
94. ZUGOR V, Kuhn R, Engelhard K, Poth S, et al
    The Value of Endorectal Magnetic Resonance Imaging of the Prostate in Improving the Detection of Anterior Prostate Cancer.
    Anticancer Res. 2016;36:4279-83.
    PubMed     Text format     Abstract available
    
    
    
95. SINHA AA, Pomroy FE Jr, Wilson MJ
    Concurrent Androgen and Estrogen Ablation and Inhibition of Steroid Biosynthetic Enzyme Treatment for Castration-resistant Prostate Cancer.
    Anticancer Res. 2016;36:3847-54.
    PubMed     Text format     Abstract available
    
    
    
96. KADONO Y, Nohara T, Kadomoto S, Nakashima K, et al
    Investigating Urinary Conditions Prior to Robot-assisted Radical Prostatectomy in Search of a Desirable Method for Evaluating Post-prostatectomy Incontinence.
    Anticancer Res. 2016;36:4293-8.
    PubMed     Text format     Abstract available
    
    
    
97. ZUGOR V, Poth S, Kuhn R, Bernat MM, et al
    Is an Extended Prostate Biopsy Scheme Associated with an Improvement in the Accuracy Between the Biopsy Gleason Score and Radical Prostatectomy Pathology? A Multivariate Analysis.
    Anticancer Res. 2016;36:4285-8.
    PubMed     Text format     Abstract available
    
    
    
98. DI PIERRO GB, Grande P, Mordasini L, Danuser H, et al
    Safety and Efficacy of Robot-assisted Radical Prostatectomy in a Low-volume Center: A 6-year Single-surgeon Experience.
    Anticancer Res. 2016;36:4201-7.
    PubMed     Text format     Abstract available
    
    
    July 2016
99. SAKAUE M, Maeda K, Ohno S, Ito T, et al
    Screening for Identification of Personalized Food to Promote Adiponectin Secretion in Patients with Cancer.
    Anticancer Res. 2016;36:3673-7.
    PubMed     Text format     Abstract available
    
    
    
100. KARIHTALA P, Rissanen T, Tuominen H
     Male Malignant Phyllodes Breast Tumor After Prophylactic Breast Radiotherapy and Bicalutamide Treatment: A Case Report.
     Anticancer Res. 2016;36:3433-6.
     PubMed     Text format     Abstract available
     
     
     June 2016
101. ONISHI T, Shibahara T, Masui S, Sugino Y, et al
     Efficacy of Ethinylestradiol Re-challenge for Metastatic Castration-resistant Prostate Cancer.
     Anticancer Res. 2016;36:2999-3004.
     PubMed     Text format     Abstract available
     
     
     
102. GRISANTI S, Antonelli A, Buglione M, Almici C, et al
     Analysis of Circulating Tumor Cells in Prostate Cancer Patients at PSA Recurrence and Review of the Literature.
     Anticancer Res. 2016;36:2975-81.
     PubMed     Text format     Abstract available
     
     
     
103. MAKI S, Itoh Y, Kubota S, Okada T, et al
     Late Rectal Toxicity from Image-guided Intensity Modulated Radiotherapy for Prostate Cancer.
     Anticancer Res. 2016;36:2967-73.
     PubMed     Text format     Abstract available
     
     
     May 2016
104. KANEMOTO A, Matsumoto Y, Sugita T, Abe E, et al
     Risk Factors and Time to Occurrence of Genitourinary Toxicity After External Beam Radiotherapy for Prostate Cancer.
     Anticancer Res. 2016;36:2441-4.
     PubMed     Text format     Abstract available
     
     
     April 2016
105. CAPOUN O, Mikulova V, Jancikova M, Honova H, et al
     Prognosis of Castration-resistant Prostate Cancer Patients - Use of the AdnaTest(R) System for Detection of Circulating Tumor Cells.
     Anticancer Res. 2016;36:2019-26.
     PubMed     Text format     Abstract available
     
     
     
106. DAVIES RS, Smith C, Lester JF
     Third-line Enzalutamide Following Docetaxel and Abiraterone in Metastatic Castrate-resistant Prostate Cancer.
     Anticancer Res. 2016;36:1799-803.
     PubMed     Text format     Abstract available
     
     
     
107. OU YC, Yang CK, Chang KS, Wang J, et al
     Prevention and Management of Complications During Robotic-assisted Laparoscopic Radical Prostatectomy Following Comprehensive Planning: A Large Series Involving a Single Surgeon.
     Anticancer Res. 2016;36:1991-8.
     PubMed     Text format     Abstract available
     
     
     
108. WINDRICHOVA J, Fuchsova R, Kucera R, Topolcan O, et al
     Testing of a Novel Cancer Metastatic Multiplex Panel for the Detection of Bone-metastatic Disease - a Pilot Study.
     Anticancer Res. 2016;36:1973-8.
     PubMed     Text format     Abstract available
     
     
     March 2016
109. CUI YX, Evans BA, Jiang WG
     New Roles of Osteocytes in Proliferation, Migration and Invasion of Breast and Prostate Cancer Cells.
     Anticancer Res. 2016;36:1193-201.
     PubMed     Text format     Abstract available
     
     
     
110. FRAGNI M, Bonini SA, Stabile A, Bodei S, et al
     Inhibition of Survivin Is Associated with Zoledronic Acid-induced Apoptosis of Prostate Cancer Cells.
     Anticancer Res. 2016;36:913-20.
     PubMed     Text format     Abstract available
     
     
     
111. WEEKS HP, Sanders AJ, Kynaston HG, Jiang WG, et al
     The Association Between WAVE1 and -3 and the ARP2/3 Complex in PC 3 Cells.
     Anticancer Res. 2016;36:1135-42.
     PubMed     Text format     Abstract available
     
     
     
112. OWEN S, Sanders AJ, Mason MD, Jiang WG, et al
     Targeting of Receptor Activator of Nuclear Kappa B (RANK) in PC-3 Cells Increases Cell Proliferation and Matrix Adhesion In Vitro.
     Anticancer Res. 2016;36:1127-34.
     PubMed     Text format     Abstract available
     
     
     February 2016
113. YENCILEK F, Yilmaz SG, Yildirim A, Gormus U, et al
     Apolipoprotein E Genotypes in Patients with Prostate Cancer.
     Anticancer Res. 2016;36:707-11.
     PubMed     Text format     Abstract available
     
     
     
114. BURKE AJ, Ali H, O'Connell E, Sullivan FJ, et al
     Sensitivity Profiles of Human Prostate Cancer Cell Lines to an 80 Kinase Inhibitor Panel.
     Anticancer Res. 2016;36:633-41.
     PubMed     Text format     Abstract available
     
     
     January 2016
115. YAMASAKI M, Yuasa T, Yamamoto S, Hayashi T, et al
     Efficacy and Safety Profile of Enzalutamide for Japanese Patients with Castration-resistant Prostate Cancer.
     Anticancer Res. 2016;36:361-5.
     PubMed     Text format     Abstract available
     
     
     
116. CHOI KW, Suh H, Oh HL, Ryou C, et al
     p21CIP1 Induces Apoptosis via Binding to BCL2 in LNCaP Prostate Cancer Cells Treated with MCS-C3, A Novel Carbocyclic Analog of Pyrrolopyrimidine.
     Anticancer Res. 2016;36:213-20.
     PubMed     Text format     Abstract available
     
     
     
117. RAMACHANDRAN K, Speer C, Nathanson L, Claros M, et al
     Role of DNA Methylation in Cabazitaxel Resistance in Prostate Cancer.
     Anticancer Res. 2016;36:161-8.
     PubMed     Text format     Abstract available
     
     
     
118. ELGQVIST J, Timmermand OV, Larsson E, Strand SE, et al
     Radiosensitivity of Prostate Cancer Cell Lines for Irradiation from Beta Particle-emitting Radionuclide 177Lu Compared to Alpha Particles and Gamma Rays.
     Anticancer Res. 2016;36:103-9.
     PubMed     Text format     Abstract available
     
     
     
119. LINDHOLM PF, Hwang YS
     LPA Increases Tumor Growth and Bone Destruction Through Enhancement of Osteoclastogenic Cytokines.
     Anticancer Res. 2016;36:61-70.
     PubMed     Text format     Abstract available
     
     
     December 2015
120. SHIOTA M, Takeuchi A, Sugimoto M, Kashiwagi E, et al
     Prognostic Impact of Serum Testosterone and Body Mass Index Before Androgen-deprivation Therapy in Metastatic Prostate Cancer.
     Anticancer Res. 2015;35:6925-32.
     PubMed     Text format     Abstract available
     
     
     
121. SPICK C, Polanec SH, Mitterhauser M, Wadsak W, et al
     Detection of Bone Metastases Using 11C-Acetate PET in Patients with Prostate Cancer with Biochemical Recurrence.
     Anticancer Res. 2015;35:6787-91.
     PubMed     Text format     Abstract available
     
     
     
122. RAATIKAINEN S, Aaaltomaa S, Karja V, Soini Y, et al
     Increased Peroxiredoxin 6 Expression Predicts Biochemical Recurrence in Prostate Cancer Patients After Radical Prostatectomy.
     Anticancer Res. 2015;35:6465-70.
     PubMed     Text format     Abstract available
     
     
     November 2015
123. MAIER GS, Horas K, Kurth AA, Lazovic D, et al
     Prevalence of Vitamin D Deficiency in Patients with Bone Metastases and Multiple Myeloma.
     Anticancer Res. 2015;35:6281-5.
     PubMed     Text format     Abstract available
     
     
     October 2015
124. AMBROSIO MR, Rocca BJ, Barone A, Ginori A, et al
     Lymphatic Vascularization in Prostate Adenocarcinoma: Correlation with Tumor Grade, Androgen Withdrawal and Prognosis.
     Anticancer Res. 2015;35:5595-600.
     PubMed     Text format     Abstract available
     
     
     
125. NOLTE E, Sobel A, Wach S, Hertlein H, et al
     The New Semisynthetic Cardenolide Analog 3beta-[2-(1-Amantadine)-1-on-ethylamine]-digitoxigenin (AMANTADIG) Efficiently Suppresses Cell Growth in Human Leukemia and Urological Tumor Cell Lines.
     Anticancer Res. 2015;35:5271-5.
     PubMed     Text format     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: